Previous | Home | EndoTODAY | List | Next


[Gastric MALToma - a personal guide]

º¸´Ù ÀÚ¼¼ÇÑ ³»¿ëÀº EndoTODAY MALToma¸¦ Âü°íÇϽñ⠹ٶø´Ï´Ù.


[¾Öµ¶ÀÚ Áú¹®] Gastric MALToma°¡ ÀǽɵǴ ȯÀÚ°¡ À־ Áú¹®µå¸³´Ï´Ù. MALToma·Î Áø´ÜµÈ °æ¿ì Ãß°¡ °Ë»ç·Î ¸ðµç ȯÀÚ¿¡¼­ °ñ¼ö°Ë»ç³ª CT EUS¸¦ ¸ðµÎ ÇϽôÂÁö¿ä ? ¾Æ´Ï¸é ¼±º°Çؼ­ ÇÑ´Ù¸é ¾î´À °æ¿ì¿¡ EUS³ª °ñ¼ö°Ë»ç CT¸¦ ÇϽôÂÁö? ¸ðµç ȯÀÚ¿¡¼­ ÇÑ´Ù¸é °Ë»ç°á°ú ¶§¹®¿¡ Ä¡·á¹æħÀ» ¹Ù²Ù°Ô µÇ´Â °æ¿ì°¡ ½ÇÁ¦ ¸¹ÀºÁö¿ä? ³»½Ã°æ ¼Ò°ßÀÌ °­·ÂÀÌ ÀǽɵǴµ¥ Á¶Á÷ °á°ú À½¼ºÀÎ °æ¿ì ¾ó¸¶°£°ÝÀ¸·Î ³»½Ã°æ °Ë»ç¸¦ ÇϽôÂÁö¿ä?


[ÀÌÁØÇà ´äº¯] ÁÁÀº Áú¹® °¨»çÇÕ´Ï´Ù. Á¦ ÀÇ°ßÀº ¾Ö¸ÅÇÏÁö¸¸.... CT´Â ¸ðµÎ ÇÏ°í ÀÖ½À´Ï´Ù. EUS¿Í bone marrow´Â Àû´çÈ÷ ÇÏ°í ÀÖ½À´Ï´Ù. ¹Ý Á¤µµ ÇÑ´Ù°í º¸½Ã¸é µË´Ï´Ù. ½ÉÇØ º¸À̸é ÇÏ°í °¡º­¿ö º¸À̸é ÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. °Ë»ç °á°ú ¶§¹®¿¡ Ä¡·á¹æħÀ» ¹Ù²Ù´Â °æ¿ì´Â ¾øÁö ¾ÊÁö¸¸ ¸Å¿ì µå¹´´Ï´Ù. Áö±Ý±îÁö °ñ¼ö ħÀ±ÀÌ ÀÖ¾ú´ø °æ¿ì´Â ÇÑ ¸í »ÓÀ̾ú½À´Ï´Ù. ³»½Ã°æ ¼Ò°ß¿¡¼­ MALToma°¡ ÀǽɵǴµ¥ Á¶Á÷°Ë»ç¿¡¼­ ¾È ³ª¿À¸é 2°³¿ù ÈÄ Àç°ËÇÏ°í ÀÖ½À´Ï´Ù. »ç½Ç 1³â ÈÄ¿¡ Çصµ º° ¹®Á¦´Â ¾ø½À´Ï´Ù¸¸...... MALT ¸²ÇÁÁ¾¿¡ ´ëÇÑ EndoTODAY AtlasÀڷḦ À̹ø ±âȸ¿¡ ¾à°£ updateÇÏ¿´½À´Ï´Ù.

1. °³³ä°ú ºÐ·ù

À§ MALT ¸²ÇÁÁ¾ÀÇ °³³äÀº 1983³â Isaacson°ú Wright¿¡ ÀÇÇØ Ã¼°èÈ­µÇ¾ú°í, ÃÖ±Ù 2008³â WHO ºÐ·ù¿¡¼­´Â extranodal marginal zone B-cell lymphoma of MALT¶ó´Â À̸§À¸·Î ºÒ¸®°í ÀÖ½À´Ï´Ù. À§ MALT ¸²ÇÁÁ¾ÀÇ Áø´Ü°ú Ä¡·á¿¡ ´ëÇÑ ÀûÁö ¾ÊÀº È¥¼±ÀÌ Àִµ¥ ÀÌ´Â À§ MALT ¸²ÇÁÁ¾¿¡ ´ëÇÑ °³³äÀÌ º¯ÇÏ¿´±â ¶§¹®ÀÔ´Ï´Ù. ¾ö¹ÐÇÏÁö´Â ¾ÊÁö¸¸ °³³äÀûÀ¸·Î ¼³¸íÇÏ¸é ´ÙÀ½°ú °°½À´Ï´Ù.

À§ MALT ¸²ÇÁÁ¾À̶ó´Â ÁúȯÀÌ Ã³À½ Á¤¸³µÉ ¹«·Æ¿¡´Â B-¼¼Æ÷ ¸²ÇÁÁ¾À» (1) °íµµ ¿ä¼Ò°¡ ¾ø´Â MALT ¸²ÇÁÁ¾ (MALToma without high grade component), (2) °íµµ ¿ä¼Ò¸¦ °¡Áø MALT ¸²ÇÁÁ¾ (MALToma with high grade component), (3) ¹Ì¸¸¼º °Å´ë B-¼¼Æ÷ ¸²ÇÁÁ¾ (= ±¤¹üÀ§Å«B¼¼Æ÷¸²ÇÁÁ¾, diffuse large B-cell lymphoma, DLBCL)ÀÇ 3 ±ºÀ¸·Î ±¸ºÐÇÏ¿´½À´Ï´Ù.

ÀÌ Áß µÎ ¹ø°¿¡ ÇØ´çÇÏ´Â °íµµ ¿ä¼Ò¸¦ °¡Áø MALT ¸²ÇÁÁ¾Àº Helicobacter pylori Á¦±ÕÄ¡·á¿¡ ¹ÝÀÀÇÏ´Â °æ¿ìµµ ÀÖÁö¸¸, ´ëºÎºÐÀº DLBCL¿Í ºñ½ÁÇÑ °æ°ú¸¦ º¸ÀÔ´Ï´Ù. µû¶ó¼­ ÃÖ±Ù¿¡´Â °íµµ ¿ä¼Ò°¡ ¾ø´Â MALT ¸²ÇÁÁ¾¸¸À» extranodal marginal zone B-cell lymphoma of MALT¶ó°í ºÎ¸£°í ³ª¸ÓÁö µÎ ±ºÀº DLBCL·Î ÅëĪÇÏ°í ÀÖ½À´Ï´Ù.

º´¸®Çб³°ú¼­¿¡¼­´Â À§Àå°ü DLBCL¸¦ MALT ¸²ÇÁÁ¾ ¿ä¼Ò¸¦ °¡Áø °æ¿ì¿Í MALT ¸²ÇÁÁ¾ ¿ä¼Ò°¡ ¾ø´Â °æ¿ì·Î ³ª´©±âµµ ÇÕ´Ï´Ù.


Âü°í: Dawsons criteria for primary GI lymphoma

(1) Originally used to define a primary intestinal lymphoma now modified to define gastric lymphomas also.

(2) Inclusion criteria: The organ is predominantly involved, and the intra-abdominal lymphadenopathy, if present, corresponds to the expected lymphatic drainage of the organ.

(3) Exclusion criteria: palpable subcutaneous nodule, mediastinal lymphadenopath, abnormal leucocytes on PBS/BM aspirate, splenic/hepatic involvement


2. ³»½Ã°æ ¼Ò°ß

ÀüÅëÀûÀ¸·Î À§ MALT ¸²ÇÁÁ¾ÀÇ ³»½Ã°æÀû Ư¡Àº ¡®Æ¯Â¡ÀÌ ¾ø´Â °Í¡¯À̶ó°í °¡¸£Ä¡°í ¹è¿ö¿Ô½À´Ï´Ù. ±×¸¸Å­ ´Ù¾çÇÑ ¸ð¾çÀ» °¡Áú ¼ö ÀÖ´Ù´Â ÀǹÌÀÏ °ÍÀÔ´Ï´Ù.

ƯÈ÷ ¡®°íµµ ¿ä¼Ò¸¦ °¡Áø MALT ¸²ÇÁÁ¾¡¯À» À§ MALT ¸²ÇÁÁ¾¿¡ Æ÷ÇÔ½ÃÅ°´ø ½ÃÀý¿¡´Â ÁøÇà À§¾Ï°ú ºñ½ÁÇÑ ÇüŸ¦ º¸ÀÎ °æ¿ìµµ ÀÖ¾ú½À´Ï´Ù. ±×·¯³ª ¡®°íµµ ¿ä¼Ò¸¦ °¡Áø MALT ¸²ÇÁÁ¾¡¯À» MALT ¸²ÇÁÁ¾¿¡ Æ÷ÇÔ½ÃÅ°Áö ¾Ê°Ô µÇ¸é¼­ À§ MALT ¸²ÇÁÁ¾Àº ´ëºÎºÐ À§¿°À̳ª Á¶±âÀ§¾Ï°ú ºñ½ÁÇÑ ¸ð¾çÀ» º¸ÀÌ°Ô µÇ¾ú½À´Ï´Ù.

³»½Ã°æÀû Ư¡¿¡ µû¸¥ ºÐ·ù¹ýÀº ¸¹Àº ÀúÀÚµéÀÌ Á¦½ÃÇÏ°í ÀÖÀ¸³ª ÇÊÀÚ´Â ´ÙÀ½°ú °°ÀÌ ³ª´©°í ÀÖ½À´Ï´Ù. (1) gastritis-like MALTomas, (2) multifocal atrophy pattern MALTomas, (3) multinodular MALToma, (4) ulcerative MALTomas, (5) polypoid MALToma, (6) EGC-like MALTomas. ½ÇÁ¦·Î´Â ¾à°£ ÁöÀúºÐÇϸ鼭 ½ÉÇÏ°í ºÒ±ÔÄ¢ÇÏ°Ô ºÐÆ÷ÇÏ´Â ¹Ì¶õ¼º À§¿°°ú ºñ½ÁÇÑ ÇüŸ¦ º¸ÀÌ´Â °æ¿ì°¡ °¡Àå ¸¹½À´Ï´Ù.

(1) Gastritis-like MALTomas

(2) Multifocal atrophy pattern MALTomas

(3) Multinodular MALToma

(4) Ulcerative MALTomas

(5) Polypoid MALToma

(6) EGC-like MALTomas


3. º´¸® ¼Ò°ß

À§ MALT ¸²ÇÁÁ¾ÀÇ º´¸®ÇÐÀû Ư¡Àº ´ÙÀ½°ú °°Àº 5 °¡Áö ¼Ò°ßÀ¸·Î Á¤¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù.

(1) Á¤»óÀûÀÎ Peyer¡¯s patchÀÇ ¸²ÇÁÁ¶Á÷À» ´àÀº ¹ÝÀÀ¼º ¸²ÇÁ¿©Æ÷°¡ ÀÖ°í,

(2) marginal zone/monocytoid B-¼¼Æ÷µéÀÌ ÀÖÀ¸¸ç,

(3) lymphoepithelial lesion, Áï 3°³ ÀÌ»óÀÇ marginal zone cellÀÌ »óÇÇ È¤Àº À§ ¼±¿¡ ħ¹üÇÏ¿© »óÇǼ¼Æ÷ÀÇ È£»ê¼º º¯¼ºÀ» º¸ÀÌ´Â º´º¯À» º¸À̸ç,

(4) ¼Ò¸²ÇÁ±¸¿Í ÇüÁú¼¼Æ÷ ħÀ±°ú ÇÔ²² (Dutcher ¼Òü¸¦ °¡Áú ¼ö ÀÖ´Ù),

(5) ¿©Æ÷¾Æ¼¼Æ÷(centroblast)¿Í ¸é¿ª¾Æ¼¼Æ÷(immunoblast)°¡ ÃâÇöÇÑ´Ù.


½ÇÁ¦·Î ÀÌ¿Í °°Àº ¼Ò°ßµéÀº µðÁöÅÐÀûÀÎ ´Ü°èº¸´Ù´Â ¾Æ³ª·Î±×ÀûÀÎ ½ºÆåÆ®·³À» °¡Áö°í ÀÖÀ¸¹Ç·Î Wotherspoon µîÀÌ ³ª´« scoring systemÀÌ ÀÚÁÖ »ç¿ëµË´Ï´Ù.


Wotherspoon 3 ȤÀº 4°¡ ³ª¿À¸é °í¹ÎÀÔ´Ï´Ù. ÇÑ ¸®ºä¿¡¼­´Â PCR·Î Æò°¡ÇÑ monoclonality·Î ¾ÏÁø´ÜÀ» ÇÑ´Ù°í µÇ¾î ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ ¶ÇÇÑ Ç¥ÁØÀûÀÎ ¹æ¹ýÀº ¾Æ´Õ´Ï´Ù. Àú´Â º´¸®°ú ¼±»ý´ÔÀ» ã¾Æ°¡¼­ ÇÔ²² ½½¶óÀ̵带 º¸¸é¼­ °í¹ÎÇÏ´Â ¹æ¹ýÀ» ÅÃÇÕ´Ï´Ù. PCRº¸´Ù ³´´Ù°í »ý°¢ÇÕ´Ï´Ù.


4. Staging

À§ MALT ¸²ÇÁÁ¾Àº ¹«Áõ»ó ¼ºÀÎÀÇ °Ç°­°ËÁø¿¡¼­ ¹ß°ßµÇ´Â °æ¿ì°¡ ¸¹°í, H. pylori Á¦±ÕÄ¡·á·Î È£ÀüµÇ´Â ¿¹°¡ 80% ÀÌ»óÀ̹ǷΠstagingÀ» ¼ÒȦÈ÷ Çϱ⠽±½À´Ï´Ù. ±×·¯³ª ÁÖÀÇÇØ¾ß ÇÒ °üÇàÀÔ´Ï´Ù. ³»½Ã°æ, Á¶Á÷°Ë»ç, CT´Â ±âº»ÀÔ´Ï´Ù. ¹®Á¦´Â EUS¿Í bone marrow °Ë»ç¸¦ ¸ðµÎ ÇØ¾ß Çϴ°¡ÀÔ´Ï´Ù. Ç¥ÁØÀûÀÎ ¹®Çå¿¡¼­´Â ´ç¿¬È÷ µÎ °Ë»ç¸¦ ¸ðµÎ ÇÏ´Â °ÍÀ¸·Î µÇ¾î ÀÖ½À´Ï´Ù.

Àú´Â ¿ö³« °æ¹ÌÇÑ À§ MALT ¸²ÇÁÁ¾À» ¸¹ÀÌ º¸°í À־ ¸ðµç ȯÀÚ¿¡¼­ EUS¿Í bone marrow¸¦ ½ÃÇàÇÏÁö´Â ¾Ê°í ÀÖ½À´Ï´Ù. Á¤È®ÇÑ ±âÁØÀº ¾øÀÌ Ä¡·áÇÏ°í Àִµ¥ ¾ÆÁ÷±îÁö ¹®Á¦´Â ¾ø¾ú½À´Ï´Ù. ´ë·« Àý¹ÝÀº °Ë»çÇÏ°í Àý¹ÝÀº °Ë»çÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. ¾ðÁ¨°¡ ¸íÈ®È÷ Á¤¸®ÇØ¾ß ÇÒ À̽´¶ó°í »ý°¢ÇÏÁö¸¸ ¾ÆÁ÷ °æÇèÀÌ ºÎÁ·ÇÏ°í Âü°íÇÒ ¹®Çåµµ ¾ø½À´Ï´Ù. ¿ÏÀüÈ÷ ÀÓ»ó°¡ÀÇ °¨(Êï)¿¡ ÀÇÁ¸Çؼ­ ¼±ÅÃÇÏ°í ÀÖ´Ù°í º¸½Ã¸é µË´Ï´Ù.


5. Ä¡·á

º´±â°áÁ¤À» À§ÇÑ °Ë»ç (CT, EUS, °ñ¼ö°Ë»ç µî) ÈÄ Á¡¸·À̳ª À§Á¡¸·ÇÏÃþ¿¡ ±¹ÇÑµÈ MALT ¸²ÇÁÁ¾À¸·Î Áø´ÜµÇ°í H. pylori °¨¿°ÀÌ µ¿¹ÝµÇ¾î ÀÖÀ¸¸é H. pylori Á¦±ÕÄ¡·á¸¦ ½ÃÇàÇÕ´Ï´Ù.Á¦±ÕÄ¡·á·Î ÀÎÇÏ¿© ¿ÏÀü°üÇØ¿¡ µµ´ÞÇÏ´Â ºñÀ²Àº ´ë·« 80% Á¤µµ·Î ¾Ë·ÁÁ® ¿Ô½À´Ï´Ù. ÃÖ±Ù¿¡´Â °Ç°­°ËÁøÀ» ÅëÇÏ¿© °æ¹ÌÇÑ MALT ¸²ÇÁÁ¾ÀÌ ¸¹¾ÆÁ®¼­ °ú°Åº¸´Ù Á¦±ÕÄ¡·áÀÇ È¿°ú°¡ ´õ¿í ÁÁ´Ù´Â °ßÇØ°¡ ÀÖ½À´Ï´Ù.

Á¦±ÕÄ¡·á ÈÄ °üÇØÀÇ ¿©ºÎ´Â ³»½Ã°æ°ú Á¶Á÷°Ë»ç ¼Ò°ßÀ» Á¾ÇÕÇÏ¿© ÆÇ´ÜÇÕ´Ï´Ù. ¹°·Ð Á¶Á÷°Ë»ç°¡ ´õ Áß¿äÇÕ´Ï´Ù. ±×·±µ¥ 10³â ÀüºÎÅÍ GELA staging systemÀ̶ó´Â °ÍÀÌ ¼Ò°³µÇ¾î Å« È¥¶õÀ» ¸¸µé°í ÀÖ½À´Ï´Ù. ³Ê¹« ¸¹Àº ¹®Á¦°¡ ÀÖ´Â ½Ã½ºÅÛÀÌÁö¸¸ ƯÈ÷ ´ÙÀ½ µÎ °¡Áö´Â Á¤¸» °ñÄ¡ÀÔ´Ï´Ù. (1) pMRD (probable minimal residual disease)°¡ °üÇØ(remission)·Î Çؼ®µÈ´Ù´Â °ÍÀÔ´Ï´Ù. pMRD¸¦ ±×´ë·Î ¹ø¿ªÇϸé "¾Æ¸¶µµ ¾ÏÀÌ Á¶±Ý ³²¾ÆÀÖ´Â °Í °°´Ù"Àε¥ À̸¦ °üÇØ·Î Çؼ®ÇØ¾ß ÇÏ´Ù´Ï...... À̸¦ ÀÌÇØÇÒ ¼ö Àִ ȯÀÚ³ª ÀÇ»ç´Â ¾ø½À´Ï´Ù. ¸íĪÀ» ¹Ù²ã¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù. (2) NC (no change)ÀÔ´Ï´Ù. ¾ð²ý »ý°¢ÀÌ "º¯È­°¡ ¾øÀ¸´Ï ÁÁÀº °ÍÀ̱¸³ª"ÀÔ´Ï´Ù. ±×·¯³ª ÀüÇô È£ÀüÀÌ ¾ø´Ù´Â °ÍÀÔ´Ï´Ù. Áï ¸Å¿ì ³ª»Û °ÍÀÌ no changeÀÔ´Ï´Ù. Àúµµ Çò°¥¸° °æ¿ì°¡ ÀÖ¾ú½À´Ï´Ù. ¸íĪÀ» ¹Ù²ã¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù. ¿©ÇÏÆ° ¾î¶² º´¸®°ú Àǻ簡 ÇѽÉÇÑ systemÀ» Á¦¾ÈÇÏ¿´´Âµ¥ ³Ê¹« ¸¹ÀÌµé »ç¿ëÇÏ°í ÀÖ´Â °Í °°½À´Ï´Ù.

Á¦±ÕÄ¡·á·Î °üÇØ¿¡ µµ´ÞÇÏÁö ¾Ê´Â ¿¹´Â ´ëºÎºÐ (1) Á¡¸·ÇÏÃþÀ» ³Ñ¾î ħ¹üµÇ¾î Àְųª, (2) °íµµ ¿ä¼Ò¸¦ °¡Áö°í Àְųª, (3) ³»½Ã°æÃÊÀ½ÆÄ¿¡¼­ À§ ÁÖÀ§ÀÇ ¸²ÇÁÀýÀÌ Ä§¹üµÇ¾î Àְųª, (4) t(11;18)(q21;q21)¿Í °°Àº ¿°»öüÀÌ»óÀÌ Á¸ÀçÇÏ´Â °æ¿ìÀÔ´Ï´Ù. ¾Æ·¡´Â »ï¼º¼­¿ïº´¿ø¿¡¼­ MALT ¸²ÇÁÁ¾ ȯÀÚÀÇ ÀÓ»ó°æ°ú¸¦ ¿ä¾àÇÑ ³»¿ëÀÔ´Ï´Ù.

Á¦±ÕÄ¡·á·Î °üÇØ¿¡ µµ´ÞÇÑ È¯ÀÚÀÇ Àç¹ß·üÀº ´ë°­ 10% Á¤µµ·Î »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. Àç¹ß¿¹ÀÇ »ó´ç¼ö´Â H. pylori ¾ç¼ºÀÔ´Ï´Ù. µû¶ó¼­ Á¦±ÕÄ¡·á¸¦ ´Ù½ÃÇÏ´Â À¯¿ëÇÑ Àü·«ÀÔ´Ï´Ù.

Á¦±ÕÄ¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â MALT ¸²ÇÁÁ¾¿¡ ´ëÇؼ­´Â ¹æ»ç¼±Ä¡·á (30 Gy Á¤µµ)°¡ °¡Àå ¸¹ÀÌ ÀÌ¿ëµÇ°í ÀÖÀ¸¸ç Ç×¾ÏÈ­Çпä¹ýÀÌ »ç¿ëµÇ±âµµ ÇÕ´Ï´Ù.


5. Further readings

(1) Seifert E. Endoscopic and bioptic diagnosis of malignant non-Hodgkin's lymphoma of the stomach. (Endoscopy 1993)


[Joel on Software]

http://www.joelonsoftware.com/À̶ó´Â À¯¸íÇÑ ÇÁ·Î±×·¡¹Ö blog¸¦ ¿î¿µÇÏ´Â JoelÀÇ Ã¥À» ¼Ò°³ÇÕ´Ï´Ù. ÇÁ·Î±×·¡¸ÓµéÀÌ ÀÏÇÏ´Â ¹æ½Ä¿¡ ´ëÇÑ ¹ø¶àÀÌ´Â ¾ÆÀ̵ð¾î ¸ðÀ½Áý´Ï´Ù. ¾à°£ cynical ÇÏÁö¸¸ Àΰ£¿¡ ´ëÇÑ ÀÌÇظ¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.

21Àå. ¼º°ú±ÞÀº ¿ÀÈ÷·Á ÇØ°¡ µÈ´Ù (227ÂÊ)

¾î¶² Æò°¡µç »ç±â¿¡ ¹ÌÄ¡´Â ¿µÇâÀº ¸ÅÇÑ°¡ÁöÀÔ´Ï´Ù. ºÎÁ¤ÀûÀÎ Æò°¡´Â »ç±â¸¦ È® ¶³¾îµå¸®´Â ¹Ý¸é, ±àÁ¤ÀûÀÎ Æò°¡´Â »ç±â³ª »ý»ê¼º¿¡ ¾Æ¹«·± ¿µÇâÀ» ¹ÌÄ¡Áö ¸øÇÕ´Ï´Ù. ³ôÀº Æò°¡¸¦ ¹Þ´Â »ç¶÷Àº ÀÌ¹Ì ÀÏÀ» Àß ÇÏ°í ÀÖ´Â »ç¶÷ÀÔ´Ï´Ù. ±×·± »ç¶÷¿¡°Ô ÁÁÀº Á¡¼ö¸¦ Áشٸé, ÀÚ½ÅÀÌ ³ôÀº Á¡¼ö¸¦ ¹ÞÀ¸·Á°í ¿­½ÉÈ÷ ÀÏÇß´ø °ÇÁö Çò°¥¸®°Ô ¸¸µé »ÓÀÔ´Ï´Ù. Ç°Áú¿¡ ÀÚ±à½ÉÀ» °®°í ¿­½ÉÈ÷ ÇÏ´Â Àü¹®°¡°¡ ¾Æ´Ï¶ó º¸»óÀ» ¹Ù¶ó°í ¿òÁ÷ÀÌ´Â Æĺí·ÎÇÁ °³Ã³·³ µË´Ï´Ù...... µå¸¶¸£ÄÚ¿Í ¸®½ºÅÍ°¡ ¸»Çß´ø teamicide Çö»óÀÌ ÀϾ´Ï´Ù.


23Àå. °³¹ßÀÚ´Â ¸ÖƼŽºÅ· ±â°è°¡ ¾Æ´Õ´Ï´Ù. (243ÂÊ)

´©±º°¡¿¡°Ô µÎ °¡Áö ÀÏÀ» ½ÃÄ״µ¥, ÀÏ Çϳª´Â ¹æÄ¡ÇÏ°í ´Ù¸¥ ÀÏ¿¡¸¸ Àü³äÇÑ´Ù¸é ÀåÇÏ°Ô ¿©±â½Ê½Ã¿À. ±×·¸°Ô ÇØ¾ß ´õ ¸¹Àº ÀÏÀ» ³¡³»°í Æò±Õ ¾÷¹«½Ã°£À» ¾Õ´ç±æ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù...... ÈǸ¢ÇÑ °ü¸®ÀÚ´Â Àå¾Ö¹°À» Á¦°ÅÇؼ­ »ç¶÷µéÀÌ ÇÑ °¡Áö ÀÏ¿¡¸¸ ÁýÁßÇØ ³¡³¾ ¼ö ÀÖ°Ô ÇØÁִ åÀÓÀÌ Àڽſ¡°Ô ÀÖ´Ù´Â »ç½ÇÀ» ¾Ë¾Æ¾ß ÇÕ´Ï´Ù.

ÇÁ·Î±×·¡¸Ó°¡ ÀÎÅÍ·´Æ®¿¡ Ãë¾àÇÏ´Ù´Â »ç½ÇÀº ÀÌ¹Ì ¿©·¯ ´ë°¡µéÀÌ ÁöÀûÇÑ ¹Ù ÀÖ½À´Ï´Ù. µå¸¶¸£ÄÚ Å«Çü´Ô²²¼­´Â 'ÇÇÇÿþ¾î'¿¡¼­ »ç¶÷ÀÌ ÁýÁßÇÒ ¼ö ÀÖ´Â ÃÖ¼Ò ½Ã°£ ´ÜÀ§ÀÎ flow timeÀÇ Á߿伺À» ¿ª¼³ÇÏ°í ÀÖ½À´Ï´Ù.


28Àå. ÃøÁ¤ (284ÂÊ)

´©±º°¡ Áö½Ä ³ëµ¿ÀÚÀÇ È¿À²À» ÃøÁ¤ÇÏ·Á µé¸é ¸ðµç Áú¼­°¡ ±Þ°ÝÈ÷ ºØ±«µÅ¹ö¸®´Â, Robert D. AustinÀÌ measurement dysfunctionÀ̶ó°í ÀÏÄ´ Çö»ó¿¡ Á÷¸éÇÏ°Ô µÇ´Â °ÍÀÔ´Ï´Ù...... Á¦ ¸»À» ¹ÏÁö ¸øÇϽðڴٸé AustinÀÌ ÁöÀº 'Measuring and managing performance in organization'À» Àо½Ã°í, Á÷¿øÀ» ¿Ïº®ÇÏ°Ô ÅëÁ¦ÇÒ ¼ö ¾øÀ» ¶§ (´ëºÎºÐ ±×·¸Áö¸¸ ¸»ÀÔ´Ï´Ù) ÃøÁ¤ ¿ª±â´ÉÀÌ ÇÊ¿¬ÀûÀ¸·Î ¹ß»ýÇÑ´Ù´Â »ç½ÇÀ» ÀÌÇØÇϽñ⠹ٶø´Ï´Ù.


[±âŸ]

'Ä¡°í ºüÁö±â' ½ÄÀ̶õ Çѵ¿¾ÈÀº ½Ã½ÃÄÝÄÝÇÑ ³»¿ë±îÁö °£¼·ÇÏ´Ù°¡ ¿À·§µ¿¾È ¹æÄ¡Çعö¸®´Â °ü¸®ÇàŸ¦ ¸»ÇÕ´Ï´Ù. (311ÂÊ)

¹«¾ùº¸´Ù ÁøÂ¥ À§ÇèÇÑ ¾ÆÀ̵ð¾î°¡ Çϳª ÀÖ½À´Ï´Ù. ¹Ù·Î °èȹ°ú ¼³°è°¡ ½Ã°£³¶ºñ¶ó´Â »ý°¢ÀÔ´Ï´Ù. (327ÂÊ)

"¿¢¼¿ ÆÀÀÌ Àý´ë·Î ¹Þ¾ÆµéÀÌÁö ¾ÊÀ» °É¼¼"¶ó°í ¸»ÇÏ´õ±º¿ä. "±× ÆÀÀÇ Á¿ì¸íÀÌ ¹ºÁö ¾Æ³ª? 'ÀÇÁ¸¼ºÀ» ã¾Æ ¾ø¾Ö¶ó'¶ó³×...... ¹«½¼ ÀÏÀÌ ÀÖ´õ¶óµµ ÇÙ½É ºñÁî´Ï½º ±â´ÉÀº Á÷Á¢ ¼öÇàÇ϶ó. (336ÂÊ) ¼­ºñ½º¸¦ ¾Æ¿ô¼Ò½ÌÇϴ ȸ»ç°¡ ¼­ºñ½º¸¦ ÇÒ ¶§´Â Á¦´ë·Î µÈ °í°´ Áö¿øÀ» ¹Þ±â°¡ ¾î·Æ½À´Ï´Ù. ¾Æ¿ô¼Ò½ÌÀ» µÎ ´Ü°è°¡ ³Ñ¾î¼­¸é °ÅÀÇ ºÒ°¡´ÉÇÏ´Ù°í º¸¸é µË´Ï´Ù. (390ÂÊ)

Steath lock-in (342ÂÊ)

°³¼±ÀÌ °ú°Å¿Í ´ÜÀýÀ̶ó´Â ¹æ½ÄÀ̾´Â ¾È µÈ´Ù°í º¾´Ï´Ù. (402ÂÊ)

°æÀï»ç¿¡ ´ëÇؼ­´Â ½Å°æÀ» ²ô¼¼¿ä. ±×¸®°í ÀÚ, Àú¸¦ µû¶ó ÇϽʽÿÀ. "°æÀï»ç°¡ ¾Æ´Ï¶ó °í°´¿¡°Ô ±Í¸¦ ±â¿ïÀδÙ!" (448ÂÊ)